David Pinniger, CFA

AA
7 Years of experience

Professional background

Joined Polar Capital in 2013. Fund Manager, SV Life Sciences. Equity Research Anayst – Healthcare, Abingworth Management. Equity Research Analyst – Healthcare, Morgan Stanley.

Educational background

BA (Hons), Human Sciences, First Class. Lady Margaret Hall, Oxford University.

Performance

20.46%

Manager Annualised Return Since Inception

13.16%

Benchmark Annualised Return since Inception

Manager Performance

Manager

Benchmark

Dif.

Inception

20.46%
13.16%
7.3%

5Y

19.72%
14.13%
5.59%

Data as at 30 June 2021.

Risk Statement / Disclaimer: Data is collected by Vadevalor. Care has been taken to ensure that the information is accurate, but Vadevalor neither warrants nor guarantees the contents, nor does it accept any responsibility for errors, inaccuracies or omissions herein. Past performance does not necessarily indicate future returns and should not be the sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise. This listing is for informational purposes only. You should not construe any of this material as investment, financial or other advice.

Polar Biotechnology Fund
Value investing using fundamental analysis
Benchmark
Nasdaq Biotechnology, TR
Class
Class I Inc
ISIN
IE00B42Z4531
AUM
$ 1,488,700,000
Ongoing Charges
1.10%